X
[{"orgOrder":0,"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inositec\u2019s INS-3001 Reduces Cardiovascular Calcification","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Inositec AG"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"HAYA Therapeutics"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"HAYA Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The first project will advance lead HTX-001, an antisense oligonucleotide targeting lncRNA Wisper, a cardiac tissue-enriched driver of fibrosis in the heart and second project will aim to develop a next-generation oncology therapy targeting cancer-associated fibroblast.
Lead Product(s):
HTX-001
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: HTX-001
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Innosuisse
Deal Size: $3.3 million
Upfront Cash: Undisclosed
Deal Type: Funding
May 03, 2022
Details:
HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics HTX-001, that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.
Lead Product(s):
HTX-001
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: HTX-001
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Broadview Ventures
Deal Size: $20.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
May 20, 2021
Details:
INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies.
Lead Product(s):
INS-3001
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 05, 2020